Overview

* GE Healthcare ( GEHC ) Q3 revenue grows 6% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, despite tariff impacts

* Company raises lower end of full-year 2025 Adjusted EPS guidance

Outlook

* GE HealthCare ( GEHC ) raises lower end of full-year 2025 Adjusted EPS guidance to $4.51-$4.63

* Company expects 2025 organic revenue growth of approximately 3% year-over-year

* GE HealthCare ( GEHC ) anticipates 2025 free cash flow of at least $1.4 bln

Result Drivers

* REGIONAL PERFORMANCE - Revenue growth driven by strong demand in EMEA and US

* SEGMENT CONTRIBUTION - Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics led revenue performance

* TARIFF IMPACTS - Tariffs affected margins and EPS, partially offset by volume and price benefits

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $5.10 $5.08

Revenue bln bln (13

Analysts

)

Q3 Beat $1.07 $1.05

Adjusted (13

EPS Analysts

)

Q3 EPS $0.98

Q3 Net $446 mln

Income

Q3 $593 mln

Adjusted

Free

Cash

Flow

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for GE Healthcare Technologies Inc ( GEHC ) is $88.00, about 9.8% above its October 28 closing price of $79.40

* The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)